It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes.

The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Discover the best Black Friday deals, Fort Wayne's ranking as a top retirement spot, and Walmart's pullback on diversity policies.

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year, making it competitive with Eli Lilly & Co. Inc.'s Zepbound. The stock's early-sessions lows ...

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...